Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 3/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 4/20 | 0.33 |
| ▸ | JAK2 | O60674 | 3/20 | 0.32 |
| ▸ | FLT4 | P35916 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30205777 | 1.00 | LRRK2 (0.36) | LRRK2PDE10AIRAK4SYKEGFR | |
| SCHEMBL30205952 | 0.91 | LRRK2 (0.34) | LRRK2PDE10ASYKEGFRERBB3 | |
| SCHEMBL30205514 | 0.89 | LRRK2 (0.46) | LRRK2IRAK4JAK1JAK2 | |
| SCHEMBL24944966 | 0.89 | LRRK2 (0.46) | LRRK2IRAK4JAK1JAK2 | |
| SCHEMBL30206291 | 0.88 | LRRK2 (0.38) | LRRK2IRAK4SYK | |
| SCHEMBL24944606 | 0.88 | LRRK2 (0.38) | LRRK2IRAK4SYK | |
| SCHEMBL29173317 | 0.88 | LRRK2 (0.38) | LRRK2SYK | |
| SCHEMBL24944553 | 0.88 | LRRK2 (0.42) | LRRK2PDE10ASYKCYP1A2 | |
| SCHEMBL24944216 | 0.88 | LRRK2 (0.38) | LRRK2SYK | |
| SCHEMBL30205542 | 0.88 | LRRK2 (0.38) | LRRK2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117693503-A | Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-03-12 | — | — | CN | claimed |
| CN-117693503-A | Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-03-12 | — | — | CN | disclosed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | disclosed |